You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The Tokyo-based firm is looking to expand into the US market following a recent ¥700 million ($6.6 million) Series B financing round.
The firm is offering an additional 500,000 shares of Class A stock, bringing the total to 4 million shares, offered at $110 per share.
The single-cell genomics firm's agreements with multiple companies will cover Japan, South Korea, Taiwan, Australia, and New Zealand.
The single-cell and spatial genomics firm is seeking to raise more money from the markets a year after its $410.8 million IPO.
he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.
Labs are finding cheaper, higher-throughput ways to determine the inflection points in gene expression within a particular cell.
The de novo directional genomic hybridization technology is designed to enable the measurement of simple, complex, and heterogenous structural variants.
The firm's $42.9 million in total revenues and $.41 loss per share for the second quarter both beat the average analyst estimates.
The court also ordered a new trial to determine if 10x's products infringe reconstructed patents held by Bio-Rad Laboratories.
Two companies offering droplet-based single-cell RNA sequencing sample prep, 10x Genomics and 1Cellbio, have launched dual-indexed library preparation products.
The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.
The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.
Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.
In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.